Switzerland

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Novartis Presents Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarc...

Lead Product(s): Sacubitril,Valsartan

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Entresto

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2021

Details:

In Paradise-MI trial, patients on Entresto were 10% less likely than those on ramipril to be hospitalized for heart failure, die of cardiovascular causes or develop symptomatic heart failure.

Novartis Pharmaceuticals Corporation

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Novartis Entresto® Granted Expanded Indication in Chronic Heart Failure by FDA

Lead Product(s): Sacubitril,Valsartan

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Entresto

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 16, 2021

Details:

Entresto's label expansion is based on efficacy and safety evidence observed in PARAGON-HF, the largest and only Phase III active-controlled study to date in patients with guideline-defined HFpEF.